Comparative Pharmacology
Head-to-head clinical analysis: LATANOPROSTENE BUNOD versus YUVIWEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATANOPROSTENE BUNOD versus YUVIWEL.
LATANOPROSTENE BUNOD vs YUVIWEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprostene bunod is a nitric oxide (NO)-donating prostaglandin F2α analog. It is hydrolyzed by esterases in the eye to latanoprost acid and nitric oxide. Latanoprost acid increases uveoscleral outflow of aqueous humor via FP receptor agonism, while NO enhances trabecular meshwork outflow via soluble guanylate cyclase activation.
YUVIWEL (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces the uptake of monoamines (such as dopamine) into synaptic vesicles, thereby decreasing their release into the synaptic cleft, which reduces dopaminergic transmission implicated in hyperkinetic movement disorders.
One drop (approximately 1.5 mcg) in the affected eye(s) once daily in the evening.
No established standard dosing for YUVIWEL; drug not recognized.
None Documented
None Documented
Clinical Note
moderateTiaprofenic acid + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Carprofen."
Clinical Note
moderateMesalazine + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Mesalazine."
Clinical Note
moderateThe terminal elimination half-life of latanoprostene bunod is approximately 17 minutes for the active metabolite (latanoprost acid) after topical ocular administration. This short half-life reflects rapid systemic clearance, consistent with once-daily dosing for intraocular pressure reduction.
Terminal elimination half-life is 12 hours; steady-state reached within 48-60 hours, requiring dose adjustment in renal impairment.
The primary route of elimination is via the kidneys, with approximately 88% of the dose excreted in urine as metabolites; fecal excretion accounts for about 6%, and the remainder is excreted via other routes. Renal excretion of unchanged drug is minimal.
Renal excretion of unchanged drug accounts for 70% of clearance; biliary/fecal elimination constitutes 30%.
Category A/B
Category C
Prostaglandin Analog
Prostaglandin Analog
Balsalazide + Latanoprostene bunod
"The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Balsalazide."